Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Seeking Alpha5/22/2026Neutral
PLRX
Pliant Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$71.21M
P/E Ratio
—
EPS
$-1.83
Beta
1.22
52W High
$1.95
52W Low
$1.09
50-Day MA
$1.19
200-Day MA
$1.34
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-111.40M |
| Operating Margin | 0.00% |
| Return on Equity | -53.60% |
| Return on Assets | -25.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.69 |
| Price-to-Book | 0.44 |
| Price-to-Sales (TTM) | 3071.82 |
| EV/Revenue | 1376.69 |
| EV/EBITDA | -2.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $61.92M |
| Float | $56.61M |
| % Insiders | 2.23% |
| % Institutions | 81.95% |
Historical Volatility
HV 10-Day
39.73%
HV 20-Day
36.69%
HV 30-Day
36.05%
HV 60-Day
32.14%
HV Rank
16.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($2.50 target)
1
Strong Buy4
Hold1
Strong SellLatest News
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095 Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors
GlobeNewsWire5/11/2026Neutral
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the 2026 RBC Capital Markets Global Healthcare Conference. Bernard Coulie, M.D., Ph.D., Pliant's President and Chief Executive Officer, and Keith Cummings, M.D., Pliant's Chief Financial Officer, will participate in a fireside chat on Tuesday, May 19, 2026, at 11:30 a.m. Eastern Time.
GlobeNewsWire5/6/2026Neutral
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins αvβ8 and αvβ1.
GlobeNewsWire4/30/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026